These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
772 related articles for article (PubMed ID: 34105382)
1. Tocilizumab for the Treatment of COVID-19-Induced Cytokine Storm and Acute Respiratory Distress Syndrome: A Case Series From a Rural Level 1 Trauma Center in Western Pennsylvania. Suresh K; Figart M; Formeck S; Mehmood T; Abdel Salam M; Bassilly D J Investig Med High Impact Case Rep; 2021; 9():23247096211019557. PubMed ID: 34105382 [TBL] [Abstract][Full Text] [Related]
2. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review. Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187 [TBL] [Abstract][Full Text] [Related]
3. Tocilizumab as a Treatment for 'Cytokine Storm Syndrome' in COVID-19: A Case Report. Syam AF; Pitoyo CW; Suhendro S; Zulkarnain B; Indrasari ND; Aditianingsih D; Irawan C; Susilo A; Rumende CM; Wijaya IP; Ibrahim F; Rasmin M; Alwi I; Makmun D Acta Med Indones; 2021 Apr; 53(2):194-201. PubMed ID: 34251348 [TBL] [Abstract][Full Text] [Related]
4. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Toniati P; Piva S; Cattalini M; Garrafa E; Regola F; Castelli F; Franceschini F; Airò P; Bazzani C; Beindorf EA; Berlendis M; Bezzi M; Bossini N; Castellano M; Cattaneo S; Cavazzana I; Contessi GB; Crippa M; Delbarba A; De Peri E; Faletti A; Filippini M; Filippini M; Frassi M; Gaggiotti M; Gorla R; Lanspa M; Lorenzotti S; Marino R; Maroldi R; Metra M; Matteelli A; Modina D; Moioli G; Montani G; Muiesan ML; Odolini S; Peli E; Pesenti S; Pezzoli MC; Pirola I; Pozzi A; Proto A; Rasulo FA; Renisi G; Ricci C; Rizzoni D; Romanelli G; Rossi M; Salvetti M; Scolari F; Signorini L; Taglietti M; Tomasoni G; Tomasoni LR; Turla F; Valsecchi A; Zani D; Zuccalà F; Zunica F; Focà E; Andreoli L; Latronico N Autoimmun Rev; 2020 Jul; 19(7):102568. PubMed ID: 32376398 [TBL] [Abstract][Full Text] [Related]
5. Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence. Pelaia C; Calabrese C; Garofalo E; Bruni A; Vatrella A; Pelaia G Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802761 [TBL] [Abstract][Full Text] [Related]
6. A Comprehensive Review of Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome. Khiali S; Khani E; Entezari-Maleki T J Clin Pharmacol; 2020 Sep; 60(9):1131-1146. PubMed ID: 32557541 [TBL] [Abstract][Full Text] [Related]
7. High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients. Iglesias-Julián E; López-Veloso M; de-la-Torre-Ferrera N; Barraza-Vengoechea JC; Delgado-López PD; Colazo-Burlato M; Ubeira-Iglesias M; Montero-Baladía M; Lorenzo-Martín A; Minguito-de-la-Iglesia J; García-Muñoz JP; Sanllorente-Sebastián R; Vicente-González B; Alemán-Alemán A; Buzón-Martín L J Autoimmun; 2020 Dec; 115():102537. PubMed ID: 32843231 [TBL] [Abstract][Full Text] [Related]
8. Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: successful outcome in two critically ill patients. Cala-García JD; Sierra-Bretón JD; Cavelier-Baiz JE; Faccini-Martínez ÁA; Pérez-Díaz CE Immunotherapy; 2020 Oct; 12(15):1127-1132. PubMed ID: 32664810 [No Abstract] [Full Text] [Related]
9. Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19. Saha A; Sharma AR; Bhattacharya M; Sharma G; Lee SS; Chakraborty C Arch Med Res; 2020 Aug; 51(6):595-597. PubMed ID: 32482373 [TBL] [Abstract][Full Text] [Related]
11. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial. Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441 [TBL] [Abstract][Full Text] [Related]
12. Tocilizumab improves survival in severe COVID-19 pneumonia with persistent hypoxia: a retrospective cohort study with follow-up from Mumbai, India. Gokhale Y; Mehta R; Kulkarni U; Karnik N; Gokhale S; Sundar U; Chavan S; Kor A; Thakur S; Trivedi T; Kumar N; Baveja S; Wadal A; Kolte S; Deolankar A; Pednekar S; Kalekar L; Padiyar R; Londhe C; Darole P; Pol S; Gokhe SB; Padwal N; Pandey D; Yadav D; Joshi A; Badgujar H; Trivedi M; Shah P; Bhavsar P BMC Infect Dis; 2021 Mar; 21(1):241. PubMed ID: 33673818 [TBL] [Abstract][Full Text] [Related]
13. Impact of cytokine storm on severity of COVID-19 disease in a private hospital in West Jakarta prior to vaccination. Ramatillah DL; Gan SH; Pratiwy I; Syed Sulaiman SA; Jaber AAS; Jusnita N; Lukas S; Abu Bakar U PLoS One; 2022; 17(1):e0262438. PubMed ID: 35077495 [TBL] [Abstract][Full Text] [Related]
14. Tocilizumab challenge: A series of cytokine storm therapy experiences in hospitalized COVID-19 pneumonia patients. Borku Uysal B; Ikitimur H; Yavuzer S; Ikitimur B; Uysal H; Islamoglu MS; Ozcan E; Aktepe E; Yavuzer H; Cengiz M J Med Virol; 2020 Nov; 92(11):2648-2656. PubMed ID: 32484930 [TBL] [Abstract][Full Text] [Related]
15. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Soin AS; Kumar K; Choudhary NS; Sharma P; Mehta Y; Kataria S; Govil D; Deswal V; Chaudhry D; Singh PK; Gupta A; Agarwal V; Kumar S; Sangle SA; Chawla R; Narreddy S; Pandit R; Mishra V; Goel M; Ramanan AV Lancet Respir Med; 2021 May; 9(5):511-521. PubMed ID: 33676589 [TBL] [Abstract][Full Text] [Related]
16. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. Salvarani C; Dolci G; Massari M; Merlo DF; Cavuto S; Savoldi L; Bruzzi P; Boni F; Braglia L; Turrà C; Ballerini PF; Sciascia R; Zammarchi L; Para O; Scotton PG; Inojosa WO; Ravagnani V; Salerno ND; Sainaghi PP; Brignone A; Codeluppi M; Teopompi E; Milesi M; Bertomoro P; Claudio N; Salio M; Falcone M; Cenderello G; Donghi L; Del Bono V; Colombelli PL; Angheben A; Passaro A; Secondo G; Pascale R; Piazza I; Facciolongo N; Costantini M; JAMA Intern Med; 2021 Jan; 181(1):24-31. PubMed ID: 33080005 [TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab. Morrison AR; Johnson JM; Griebe KM; Jones MC; Stine JJ; Hencken LN; To L; Bianchini ML; Vahia AT; Swiderek J; Ramesh MS; Peters MA; Smith ZR J Autoimmun; 2020 Nov; 114():102512. PubMed ID: 32646770 [TBL] [Abstract][Full Text] [Related]
18. COVID-19: Consider IL-6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients. Chakraborty C; Sharma AR; Bhattacharya M; Sharma G; Lee SS; Agoramoorthy G J Med Virol; 2020 Nov; 92(11):2260-2262. PubMed ID: 32462717 [TBL] [Abstract][Full Text] [Related]
19. Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients. Canziani LM; Trovati S; Brunetta E; Testa A; De Santis M; Bombardieri E; Guidelli G; Albano G; Folci M; Squadroni M; Beretta GD; Ciccarelli M; Castoldi M; Lleo A; Aghemo A; Vernile L; Malesci A; Omodei P; Angelini C; Badalamenti S; Cecconi M; Cremonesi A; Selmi C; J Autoimmun; 2020 Nov; 114():102511. PubMed ID: 32713677 [TBL] [Abstract][Full Text] [Related]
20. Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case-controlled study. Rojas-Marte G; Khalid M; Mukhtar O; Hashmi AT; Waheed MA; Ehrlich S; Aslam A; Siddiqui S; Agarwal C; Malyshev Y; Henriquez-Felipe C; Sharma D; Sharma S; Chukwuka N; Rodriguez DC; Alliu S; Le J; Shani J QJM; 2020 Aug; 113(8):546-550. PubMed ID: 32569363 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]